Antibody drug conjugates (ADCs) are transforming cancer research — but how do they actually work, and what does it take to bring them safely to patients?

In this episode of Moving Medicine Forward, we speak with scientist Lidia Blasco about the science and promise of antibody drug conjugates (ADCs) in cancer research. Lidia shares her journey from pharmacy and forensic analysis to oncology research, explaining in clear terms how ADCs work, why they’re transforming treatment, and what it means to develop them responsibly. The conversation also highlights the human side of clinical trials and the patients who make medical progress possible.

01:18 – Lidia Blasco’s background and path into ADC research
02:30 – Balancing PhD work with hands‑on industry lab experience
03:40 – Antibody drug conjugates explained simply
04:45 – Why ADCs are a promising cancer treatment approach
06:26 – The goal and impact of Lidia’s PhD research platform
07:30 – Improving dosing decisions and patient safety in clinical trials
08:06 – Emerging trends and innovations in ADC development
09:27 – Advice for those considering a career in oncology research
10:43 – Honoring the patients behind the research samples
12:53 – Closing reflections and final takeaways